Law report No. GLW-5549 · filed November 17, 2026
Regulation & EnforcementReported case
DOJ Healthcare Self-Disclosure Pilot Cuts Penalties, But Timing Is Everything
DOJ's healthcare pilot offers FCA resolutions at 1.25-1.6x repayment through April 2027, but sealed qui tams and a no-partial-submission rule put compliance speed to the test.
By Marcus Bennett4 min read727 words
Holding
- DOJ healthcare self-disclosure pilot offers FCA resolutions at 1.25-1.6 times base repayment through April 22, 2027
- Relators filed a record 1,297 qui tams in FY25, 458 in healthcare, driving about 80% of record recoveries
- Pilot excludes conduct the government already knows about, including sealed whistleblower complaints
- DOJ will not review partial submissions; each must describe conduct, attach documents and quantify repayment
- Civil pilot does not address criminal exposure, which must go to DOJ's National Fraud Enforcement Division

Companies that self-disclose False Claims Act violations the government does not yet know about can now settle for 1.25 to 1.6 times a base repayment under a new DOJ healthcare self-disclosure pilot running through April 22, 2027. The deal comes with a coordinated release from the DOJ and Health and Human Services, and no corporate integrity agreement. The catch: the pilot excludes anything the government already knows about — and most of its best leads come from whistleblowers.
Relators filed a record 1,297 qui tam suits across all sectors in FY25, 458 of them in healthcare, and whistleblower cases produced about 80% of the government's record recoveries. Because those suits are filed under seal, a company weighing disclosure may already be too late.
"The race may begin before a healthcare organization even knows there is a problem," said Jose Vela Jr., a healthcare attorney at Clark Hill.
What does the pilot change for practitioners?
The pilot adds a pathway rather than replacing existing CMS and OIG programs. Historically, organizations disclosed Stark Law violations to CMS, Anti-Kickback Statute violations to OIG, and potential FCA violations to DOJ. The new program resolves overlapping federal civil and specified administrative exposure through one coordinated process with more predictable financial consequences.
Jeff McSorley, a partner in Crowell & Moring's healthcare group and former DOJ trial counsel, said the pilot is unique because it specifically addresses civil FCA exposure, which other pathways generally do not resolve. "Before this pilot program, companies that took advantage of other disclosure pathways were left in a state of limbo about their potential FCA exposure," he said.
Companies can now reduce overall financial liability, obtain a civil release, and avoid administrative consequences such as Medicare exclusion, CMS civil monetary penalties, or a costly corporate integrity agreement. McSorley expects the pilot to increase disclosures, "particularly among companies already inclined to come forward." His caveat: success depends on consistent implementation and whether companies view the benefits as justifying the risks of disclosure.
Vela put the burden on the government: "DOJ will have to demonstrate that the benefits of participating outweigh the risks of coming forward."
Shannon Sumner, a principal at consultancy PYA, noted that companies now have one point of disclosure through the DOJ Fraud Division rather than navigating separate DOJ and OIG processes. But she warned the benefit only matters if compliance can surface problems early. "If an organization does not have strong reporting, investigation and escalation processes, the benefits of a clearer disclosure pathway may not matter very much," she said.
How should companies handle possible criminal exposure?
The pilot covers civil liability only. Potential criminal conduct must be disclosed to the DOJ's new National Fraud Enforcement Division, and a company that has made a criminal disclosure there need not submit a duplicate one to seek the civil release. The same conduct — a physician compensation arrangement, for instance — may violate Stark, the Anti-Kickback Statute, the FCA, and potentially constitute criminal fraud.
Vela cautioned that a company mistakenly treating potential criminal conduct as exclusively civil may lose favorable treatment under the criminal disclosure policy. McSorley added that the Civil Fraud Section will likely evaluate self-disclosures the same way regardless of channel, but disclosing under the pilot alone does not mitigate potential criminal liability.
Are companies in a race against time?
Yes, though experts framed the race differently. Sealed qui tam suits may remain unknown to a company for months or years, so waiting for a subpoena or whistleblower complaint is the greatest risk. But all three warned against hasty disclosure. The DOJ will not review partial submissions; each must fully describe the conduct, attach supporting documents, and quantify the repayment.
"This is really a race to understand your own compliance issues," Sumner said, urging reporting systems employees trust and prompt evaluation of hotline complaints and audit findings.
Where a company lands in the 1.25-to-1.6 multiplier range depends partly on whether senior leadership was involved in the misconduct — creating a conflict when those leaders also decide whether to disclose. All three experts agreed: implicated executives should not control the investigation or the disclosure decision. The board or an independent committee, with independent counsel, should oversee it.
"A company cannot credibly demonstrate accountability while allowing potentially responsible executives to control the investigation into their own conduct," Vela said.
via corporatecomplianceinsights.com (Source)
More from Marcus Bennett
Show full bio
Market editor covering regulation, policy and their impact on International law and legal practice at Global Law Wire.
319 articles